{"schema_version":"secwatch.filing_event.v1","accession":"0001516551-24-000108","form_type":"8-K","ticker":"SKYE","cik":"0001516551","company_name":"Skye Bioscience, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.654457+00:00","generated_at":"2026-05-30T03:30:45.680557+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Skye Bioscience Q3 net loss $3.9M; cash $76.5M; nimacimab Phase 2 enrolling, interim data Q2 2025","bullets":["Net loss $3.9M in Q3 2024 vs $24.9M loss in Q3 2023; decrease driven by absence of $21.2M in-process R&D acquisition expense.","Cash and equivalents $76.5M including restricted $9.1M; court order allows release of $9M restriction before year-end.","Phase 2 obesity trial for nimacimab enrolling; interim data Q2 2025, topline data Q4 2025.","Preclinical DIO mouse model: nimacimab achieved up to 16% weight loss vs vehicle, with fat loss and lean mass preservation.","Appointed Dr. Puneet Arora as Chief Medical Officer and Paul Grayson as Chairman."],"urls":{"canonical":"https://secwatch.observer/filing/0001516551-24-000108","json":"https://secwatch.observer/filing/0001516551-24-000108.json","markdown":"https://secwatch.observer/filing/0001516551-24-000108.md","text":"https://secwatch.observer/filing/0001516551-24-000108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1516551/000151655124000108/0001516551-24-000108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1516551/000151655124000108/skye-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:30:45.680557+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}